Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$276.06 USD
+1.03 (0.37%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $276.06 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$276.06 USD
+1.03 (0.37%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $276.06 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum F VGM
Zacks News
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback
by Ekta Bagri
Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.
Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro
by Zacks Equity Research
Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL on the grounds of insufficient data. The stock falls 5%.
Alnylam's (ALNY) Onpattro sNDA Gets FDA Advisory Committee Nod
by Zacks Equity Research
Alnylam (ALNY) receives a positive opinion from the FDA's advisory committee regarding the label expansion of patisiran to treat the cardiomyopathy of transthyretin-mediated amyloidosis.
Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More
by Zacks Equity Research
Pipeline and regulatory updates from (MRNA) and Amgen (AMGN) are in focus in the biotech sector.
Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study
by Zacks Equity Research
Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high cardiovascular risk meets primary and key secondary endpoints.
Why Is Qiagen (QGEN) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics AG (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea
by Zacks Equity Research
Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.
Apellis (APLS) Focuses on Empaveli to Fuel Its Growth
by Zacks Equity Research
Apellis' (APLS) first marketed product, Empaveli, continues to be the growth driver since its launch. However, Syfovre faces some safety concerns post promising takeoff.
Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform
by Zacks Equity Research
Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.
Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.
Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate.
Alnylam (ALNY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of -28.49% and 3.91%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Viatris' (VTRS) Q2 results are likely to be impacted by foreign exchange rates. Nevertheless, momentum in the branded business is likely to have continued.
Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche
by Zacks Equity Research
Alnylam (ALNY) collaborates with Roche to co-develop and co-commercialize RNAi-based therapeutic, zilebesiran, for the treatment of hypertension in patients with high cardiovascular risk.
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio
by Zacks Equity Research
Alnylam's (ALNY) revenues continue to be driven by Amvuttra and Givlaari sales. Its existing collaboration agreement with Regeneron to develop RNAi-based candidates is progressing well.
The Zacks Analyst Blog Highlights Microsoft, Salesforce, United Parcel Service, UnitedHealth and Alnylam
by Zacks Equity Research
Microsoft, Salesforce, United Parcel Service, UnitedHealth and Alnylam are included in this Analyst Blog.
Top Research Reports for Microsoft, Salesforce & United Parcel Service
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Salesforce, Inc. (CRM) and United Parcel Service, Inc. (UPS).
BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study
by Zacks Equity Research
BridgeBio's (BBIO) shares surge on announcing positive data from a late-stage study evaluating acoramidis for patients with transthyretin amyloid cardiomyopathy.
Alnylam (ALNY) Posts Upbeat Data From Alzheimer's Disease Study
by Zacks Equity Research
Alnylam (ALNY) announces positive interim analysis data from the Part A of its early-stage study of ALN-APP in the treatment of early-onset Alzheimer's disease and cerebral amyloid angiopathy.
Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date
by Zacks Equity Research
Alnylam (ALNY) reports that the FDA has set Sep 13, 2023, as the day for the meeting of the Advisory Committee to review its sNDA application for patisiran in treating the cardiomyopathy of ATTR amyloidosis.